A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled to the Brain, or Temporary Stroke-like Symptoms

Overview

Información sobre este estudio

The purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or temporary stroke-like symptoms when given in addition to standard antiplatelet therapy.  

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Participants must be ≥ 18 years of age

- Acute non-cardioembolic stroke or high-risk TIA

- Systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct

Exclusion Criteria:

- Ischemic stroke ≤ 7 days before the index stroke event

- Index stroke following procedures or strokes due to other rare causes

- History of atrial fibrillation/flutter, left ventricular thrombus, mechanic valve or other cardioembolic source of stroke requiring anticoagulation

- History of atrial fibrillation / flutter, left ventricular thrombus, mechanical valve or other cardioembolic source of stroke requiring anticoagulation

- Previous (within 30 days of randomization or 5 half-lives of the investigational drug, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s). Registries and observational studies are allowed.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/18/24. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Alejandro Rabinstein, M.D.

Abierto para la inscripción

Contact information:

Cameron Hunter

(507) 422-0406

Hunter.Cameron@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20559174

Mayo Clinic Footer